BridgeBio Pharma, Inc. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
KKR Genetic Disorder L.P. conducted a secondary offering of 5,000,000 shares of BridgeBio common stock at $78.00/share, generating ~$390M gross proceeds ($385.8M net after $0.585/share underwriting discount). BridgeBio receives no proceeds. Underwriters: William Blair (1.25M shares), Goldman Sachs (1.25M), KKR Capital Markets (2.5M). Lock-up period: 30 days post-closing. Offering closed August 17, 2026.
Why this rating
Secondary offering by existing shareholder; zero direct capital to BridgeBio. ~5.4% of float dilutes existing holders but does not alter business operations or financial position.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.